Analysts led by Yulia Zhestkova Grigsby, a commodities strategist, looked at product supplies, price responses and anecdotes to address the issue of whether the global economy is running short of oil.
Neurocrine wants to develop new obesity drugs. It’s making an acquisition to accelerate that move.
Soleno Therapeutics’ stock is soaring on Monday in premarket after a report that Neurocrine is nearing a deal to buy the company.
